Price Action To Observe: Could Immune Design Corp See a Reversal After Breaking All Highs?

Price Action To Observe: Could Immune Design Corp See a Reversal After Breaking All Highs?

The stock of Immune Design Corp (NASDAQ:IMDZ) reached all time low today, Nov, 3 and still has $4.13 target or 14.00% below today’s $4.80 share price. This indicates more downside for the $117.61 million company. This technical setup was reported by Barchart.com. If the $4.13 PT is reached, the company will be worth $16.47 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. The stock decreased 3.03% or $0.15 during the last trading session, hitting $4.8. About 144,963 shares traded hands or 53.14% up from the average. Immune Design Corp (NASDAQ:IMDZ) has declined 63.60% since April 1, 2016 and is downtrending. It has underperformed by 64.82% the S&P500.

Analysts await Immune Design Corp (NASDAQ:IMDZ) to report earnings on November, 10. They expect $-0.68 EPS, down 83.78% or $0.31 from last year’s $-0.37 per share. After $-0.71 actual EPS reported by Immune Design Corp for the previous quarter, Wall Street now forecasts -4.23% EPS growth.

Immune Design Corp (NASDAQ:IMDZ) Ratings Coverage

Out of 2 analysts covering Immune Design (NASDAQ:IMDZ), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Immune Design has been the topic of 4 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by Leerink Swann given on Tuesday, August 18. Jefferies maintained the shares of IMDZ in a report on Wednesday, August 10 with “Buy” rating. The rating was initiated by Jefferies on Wednesday, September 9 with “Buy”.

According to Zacks Investment Research, “Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. Immune Design Corp. is headquartered in Seattle, Washington.”

Insitutional Activity: The institutional sentiment increased to 1.25 in Q2 2016. Its up 0.21, from 1.04 in 2016Q1. The ratio increased, as 8 funds sold all Immune Design Corp shares owned while 16 reduced positions. 8 funds bought stakes while 22 increased positions. They now own 9.57 million shares or 12.34% less from 10.92 million shares in 2016Q1.
Cubist Systematic Strategies Ltd Liability Corporation holds 0% or 4,550 shares in its portfolio. California State Teachers Retirement System holds 0% or 23,474 shares in its portfolio. Blackrock Fund Advisors has invested 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ). Citigroup Incorporated, a New York-based fund reported 215 shares. Baker Bros L P accumulated 148,937 shares or 0.01% of the stock. Moreover, Blackrock Advisors Lc has 0% invested in Immune Design Corp (NASDAQ:IMDZ) for 60,355 shares. Barclays Pcl accumulated 0% or 264 shares. Rhumbline Advisers has 10,089 shares for 0% of their US portfolio. Point72 Asset Mngmt Ltd Partnership accumulated 70,572 shares or 0% of the stock. Pictet Asset Mngmt Ltd holds 0.04% or 748,145 shares in its portfolio. Blackrock Group Limited has invested 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ). Tiaa Cref Management Lc has invested 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ). Morgan Stanley last reported 4,828 shares in the company. Great West Life Assurance Can has 9,836 shares for 0% of their US portfolio. Proshare Advsrs Lc has 16,372 shares for 0% of their US portfolio.

Insider Transactions: Since July 15, 2016, the stock had 4 buys, and 0 sales for $10.26 million net activity. On Tuesday, September 20 the insider COLUMN GROUP L P bought $5.00 million. COLEMAN LEWIS W had bought 40,000 shares worth $250,000 on Tuesday, September 20. $10,255 worth of Immune Design Corp (NASDAQ:IMDZ) shares were bought by Brady Stephen R. $5.00 million worth of Immune Design Corp (NASDAQ:IMDZ) was bought by Svennilson Peter.

More important recent Immune Design Corp (NASDAQ:IMDZ) news were published by: Quotes.Wsj.com which released: “News Immune Design Corp.IMDZ” on July 23, 2014, also Globenewswire.com published article titled: “Immune Design Announces Advancement of First GLAASâ„¢-based Allergy Program …”, Globenewswire.com published: “Immune Design and Gritstone Oncology Announce Clinical Collaboration for …” on May 09, 2016. More interesting news about Immune Design Corp (NASDAQ:IMDZ) was released by: Gurufocus.com and their article: “Immune Design Insider Buys Shares” with publication date: October 03, 2016.

IMDZ Company Profile

Immune Design Corp., incorporated on February 20, 2008, is a clinical-stage immunotherapy company. The Firm focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Firm is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment